1例间变性淋巴瘤激酶阳性晚期非小细胞肺癌患者的治疗方案分析及药学监护
Targeted therapeutic protocol and pharmaceutical monitoring for ALK-positive advanced non-small cell lung cancer:one case report
杨洛萍 1许耿瑞 1黄开远 1刘江红 1赵文浩2
作者信息
- 1. 深圳市龙华区中心医院药学部,广东深圳 518110
- 2. 深圳市龙华区中心医院肿瘤科,广东深圳 518110
- 折叠
摘要
间变性淋巴瘤激酶-酪氨酸激酶抑制剂(anaplastic lymphoma kinase-tyrosine kinase inhibitors,ALK-TKIs)是治疗ALK阳性晚期非小细胞肺癌的首选药物,其在使患者获益的同时也常引起一系列不良反应.该文介绍了临床药师参与1例ALK阳性肺癌患者服用克唑替尼后出现不可耐受的恶心、呕吐,以及换用恩沙替尼后出现全身大面积表皮剥脱的药学实践,协助医师处理不良反应并实施药学监护,患者后续治疗疗效显著,耐受性良好.充分体现了临床药师在肿瘤患者个体化治疗中的作用,为临床处理该类药物不良反应提供了参考.
Abstract
Anaplastic lymphoma kinase-tyrosine kinase inhibitors(ALK-TKIs)have been a first-line option for ALK-positive advanced non-small cell lung cancer.A large series of adverse reactions occur while benefiting patients.This review summarized the pharmaceutical cares for intolerable nausea and vomiting after crizotinib dosing in one patient of ALK-positive lung cancer.After switching to ensartinib,there was diffuse epidermal peeling of whole body.A clinical pharmacist assisted physicians in han-dling adverse reactions and implementing pharmaceutical monitoring.Follow-up intervention was both efficacious and well-tolerated.It fully exemplified the role of clinical pharmacists in individualized treatment of tumor patients.It provided practical ref-erences for a proper management of such adverse drug reactions.
关键词
非小细胞肺癌/间变性淋巴瘤激酶(ALK)/靶向治疗/克唑替尼/恩沙替尼/药学监护Key words
non-small cell lung cancer/anaplastic lymphoma kinase(ALK)/targeted therapy/crizotinib/ensartinib/pharma-ceutical care引用本文复制引用
出版年
2024
NETL
NSTL
万方数据